Growth Factors
CJC-1295 / Ipamorelin
GH Blend
CJC-1295 and Ipamorelin blend
Research context
This preparation combines CJC-1295, a GHRH receptor analogue, with ipamorelin, a selective growth hormone secretagogue receptor (GHS-R1a) agonist. The two act at distinct receptors, and the combination appears in literature examining additive effects on pituitary secretion in cell and animal preparations.
Common assays: Component identity by LC-MS · Purity per component · Pituitary secretion assays
Specification
| Designation | GH Blend |
|---|---|
| Full name | CJC-1295 and Ipamorelin blend |
| Components | CJC-1295 · Ipamorelin |
| Formats | 10 mL Vial · 15 mL Advanced Liquid Peptide Spray |
| Solubility | Bacteriostatic water, sterile water |
| Storage | Lyophilised: −20 °C. Reconstituted: 2–8 °C. |
| Current lot | CI1010N0926 → |
CJC-1295 / Ipamorelin COA: certificates of analysis by lot
4 lots of CJC-1295 / Ipamorelin have a published certificate of analysis from AxisPharm, LLC, an independent laboratory. Each certificate reports the laboratory's results for that lot.
| Lot | Format | Purity (HPLC-UV) | Reported |
|---|---|---|---|
| CI1010N0926 | 10 mg / 10 mg Spray | 99.2% | 2026-09-21 |
| CI1010N1125 | 10 mg / 10 mg Spray | >99.0% | 2025-11-13 |
| CI710V1125 | 7.5 mg / 10 mg Vial | >99.0% | 2025-11-03 |
| CI715V1125 | 7.5 mg / 15 mg Vial | >99% | 2025-11-03 |
Published literature
Selected peer-reviewed references describing research involving this compound. Listed for reference only; inclusion is not a claim about any outcome.
- Raun K, Hansen BS, Johansen NL, et al.Ipamorelin, the first selective growth hormone secretagogueEuropean Journal of Endocrinology · 1998 Find on PubMed ↗
Common questions
Why are GHRH analogues and GHRPs studied together?
They act at different receptors — the GHRH receptor and GHS-R1a respectively — and published work examines whether combined engagement produces additive secretion effects in pituitary preparations.
What makes ipamorelin described as selective?
Published characterisation reports GHS-R1a agonism with minimal effect on cortisol and prolactin relative to earlier secretagogues in the same class.
Where can I see the CJC-1295 / Ipamorelin certificate of analysis?
Every published CJC-1295 / Ipamorelin lot has its own certificate page on this site, listed under "CJC-1295 / Ipamorelin COA" above. There are 4 published lots; the most recent, lot CI1010N0926, was reported on 2026-09-21 at 99.2% purity by HPLC-UV. The certificates are issued by AxisPharm, LLC, an independent laboratory.
Components, blends and pathway
Related compounds
CJC-1295
GHRH analog
A tetrasubstituted analogue of growth hormone-releasing hormone (1-29), studied in pituitary secretion research.
Tesamorelin
GHRH analog
A stabilised 44-residue GHRH analogue carrying an N-terminal hexenoyl modification.
Sermorelin
GHRH analog
The 29-residue amidated N-terminal fragment of growth hormone-releasing hormone.
Tesamorelin / Ipamorelin
GH Blend
A prepared blend pairing a full-length GHRH analogue with a selective ghrelin receptor secretagogue.